Xeris Biopharma Holdings XERS
NASDAQ XERS
$10.80 +0.02 (+0.14%)
As of: Oct 22, 2026 · 11:07 AM EDT

Xeris Biopharma Holdings (XERS) Long-Term Debt Repayments (2022)

Updated

Xeris Biopharma Holdings' Long-Term Debt Repayments was $43.5 million in FY2022.

Analysis

Xeris Biopharma Holdings (XERS) Long-Term Debt Repayments (2022) Analysis & Trends

  • Per Business Quant data, Long-Term Debt Repayments in earlier years was $25.09 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,172.05 Bn 1,140.63 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 636.25 Bn 554.77 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.38 Bn 476.49 Bn 12.70 Bn 2.00 Bn
4 Merck 377.92 Bn 332.30 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 304.19 Bn 268.18 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 267.24 Bn 240.93 Bn 12.86 Bn 2.46 Bn
7 Amgen 242.06 Bn 197.46 Bn 7.24 Bn -
8 Gilead Sciences 193.78 Bn 167.97 Bn 6.22 Bn 17.00 Mn
9 Pfizer 172.54 Bn 119.18 Bn 10.94 Bn -
10 Xeris Biopharma Holdings 1.87 Bn 1.43 Bn 79.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 43.50 Mn
API Access

Xeris Biopharma Holdings Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=XERS&period=max&api_key=YOUR_API_KEY